PAEP and neoplasm: Another strategy to engineer oHSVs involves retargeting them to tumor-specific receptors and de-targeting them from virus receptors through the insertion of a foreign ligand into viral gD, gH or gB, so that the virus exhibits target-specific inhibition of human tumor growth [146].